On the structure of Borel ideals in-between the ideals $\mathcal{ED}$ and $\mathrm{Fin}\otimes\mathrm{Fin}$ in the Katětov order
Abstract
For a family $\mathcal{F}\subseteq ω^ω$ we define the ideal $\mathcal{I}(\mathcal{F})$ on $ω\timesω$ to be the ideal generated by the family $\{A\subseteq ω\timesω:\exists f\in \mathcal{F}\,\forall^\infty n\, (|\{k:(n,k)\in A\}|\leq f(n))\}.$ Using ideals of the form $\mathcal{I}(\mathcal{F})$, we show that the structure of Borel ideals in-between two well known Borel ideals $\mathcal{ED} = \{A\subseteqω\timesω:\exists m \, \forall^\infty n\, (|\{k:(n,k)\in A\}|<m))\}$ and $\mathrm{Fin}\otimes\mathrm{Fin} = \{A\subseteqω\timesω:\forall^\infty n \, (|\{k:(n,k)\in A\}|<\aleph_0))\}$ in the Katětov order is fairly complicated. Namely, there is a copy of $\mathcal{P}(ω)/\mathrm{Fin}$ in-between $\mathcal{ED}$ and $\mathrm{Fin}\otimes\mathrm{Fin}$, and consequently there are increasing and decreasing chains of length $\mathfrak{b}$ and antichains of size $\mathfrak{c}$.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.